Findings of better post-TAVR survival in mixed aortic valve disease compared with pure aortic stenosis suggest that hearts already exposed to aortic regurgitation may better tolerate mild post-TAVR regurgitation.
Percutaneous coronary intervention (PCI) at the time of transcatheter aortic valve replacement (TAVR) does not appear to increase TAVR risk, according to pooled results from 11 observational studies. But the safety question isn’t fully settled.
An analysis of the TVT Registry shows a lower-than-expected stroke rate following transcatheter aortic valve replacement. But it also shows a lack of improvement over time.
Two trials comparing transcatheter (TAVR) with surgical aortic valve replacement in patients at low surgical risk found TAVR to yield equal or better outcomes. While a new indication seems certain, some key questions remain.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new analysis of the large TVT Registry provides the strongest evidence to date of a prognostic benefit from renin-angiotensin system inhibitor therapy following transcatheter aortic valve replacement.
The next waves of progress in transcatheter aortic valve replacement are likely to involve expanding indications, valve refinements and new accessory treatments.
Our experts outline their vision of ideal changes to the National Coverage Determination for programs performing transcatheter aortic valve replacement. A CMS decision is due in June 2019.
The latest PARTNER 2A analysis finds that worsening RV function is much more common after SAVR than TAVR. And it predicts greater risk for poor outcomes regardless of procedure type.
In this Q&A, Cleveland Clinic experts explore how to weigh patient age when deciding between surgical and transcathether AVR and what matters most to procedure choice for treating a degenerated aortic bioprosthesis.
The lead investigator of the pivotal SENTINEL trial explains what the data suggest about when to use the newly FDA-approved Sentinel device for cerebral embolic protection during TAVR procedures.